Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily
PTCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.80 - $46.98
Previous Close$39.23
Volume1.04M
Average Volume (3M)702.85K
Market Cap
$3.03B
Enterprise Value$2.41B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$400.20M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Feb 25, 2025EPS Estimate
-$1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.94
Shares Outstanding77,125,143
10 Day Avg. Volume789,139
30 Day Avg. Volume702,848
Standard Deviation0.14
R-Squared0.06
Alpha0.00170
Financial Highlights & Ratios
Price to Book (P/B)-2.87
Price to Sales (P/S)3.63
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit2.77
Enterprise Value/Ebitda-13.58
Forecast
1Y Price Target
$42.40Price Target Upside8.08% Upside
Rating ConsensusHold
Number of Analyst Covering13
PTC Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial Performance3Q24 revenue exceeded expectations meaningfully, in part due to steady sales of Emflaza despite it now having generic competition.
Pipeline DevelopmentsPTC continues to execute well, with Upstaza's PDUFA and sepiapterin's set for future approval, and anticipate approval for both.
Product ApprovalKebilidi was approved with a broad label, enabling the treatment of children and adults across the spectrum of disease severity.
Bears Say
Clinical Trial ResultsPhase 3 MOVE-FA trial for vatiquinone failed to meet its primary endpoint of mFARS benefit at 72 weeks in the primary analysis population.
Market ExpectationsMost investors have been ascribing minimal value to Translarna in the US given relatively low expectations for potential approval based on prior FDA feedback.
Regulatory ChallengesThe ongoing regulatory challenges and delays with Translarna in both the EU and US markets continue to pose significant hurdles for PTCT.
---
Ownership Overview
1.15% Insiders
30.05% Mutual Funds
38.69% Other Institutional Investors
12.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $19.80 and its highest was $46.98 in the past 12 months.
What is PTC Therapeutics’s market cap?
Currently, no data Available
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 96 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, beating the consensus estimate of -$1.521 by $0.131.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -$1.17.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 77,125,145 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$1.39 in its last earnings report, beating expectations of -$1.521. Following the earnings report the stock price went up 3.073%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Among the largest hedge funds holding PTC Therapeutics’s share is Blackstone Inc.. It holds PTC Therapeutics’s shares valued at 41M.
---
PTC Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$42.40 (8.08% Upside)
$42.40 (8.08% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 73%
Sector Average 73%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 23.8%
Last 30 Days ▲ 23.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.22%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
---
PTCT Earnings Call
Q3 2024
0:00 / 0:00
---
PTCT Stock 12 Month Forecast
Average Price Target
$42.40
▲(8.08% Upside)
Technical Analysis
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Best Analysts Covering PTCT
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+34.46%
assigned a buy rating 14 days ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +34.46% per trade.
---